Research programme: kynurenine aminotransferase II inhibitors - Pfizer

Drug Profile

Research programme: kynurenine aminotransferase II inhibitors - Pfizer

Alternative Names: Bicyclic and tricyclic compounds as KAT II inhibitors - Pfizer; KAT II inhibitors - Pfizer

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Heterocyclic compounds
  • Mechanism of Action Kynurenine-oxoglutarate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (SC)
  • 17 Nov 2010 Preclinical trials in Schizophrenia in USA (SC)
  • 17 Nov 2010 Pharmacodynamics data from a preclinical trial in Schizophrenia presented at the 40th Annual Meeting of the Society for Neuroscience (SfN-2010) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top